APO Research
Talk to an analyst

APO RESEARCH · REPORT

Endocrine Disruptor Testing

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Endocrine Disruptor Testing Market Analysis and Forecast 2026-2032

4 July 2026171 pages

Choose your research edition.

Industry ResearchEndocrine Disruptor Testing Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Endocrine Disruptor Testing Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Endocrine Disruptor Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Endocrine Disruptor Testing Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Endocrine Disruptor Testing Market Analysis and Forecast 2026-2032171 pages · $4,950 USD

Market perspective

The global Endocrine Disruptor Testing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Endocrine Disruptor Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Endocrine Disruptor Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Endocrine Disruptor Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Endocrine Disruptor Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Endocrine Disruptor Testing include Charles River Laboratories, Labcorp, Eurofins Scientific, PerkinElmer, Intertek, Smithers, LAUS, Xenometrix and ToxStrategies, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Endocrine Disruptor Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Endocrine Disruptor Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for Endocrine Disruptor Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Endocrine Disruptor Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Endocrine Disruptor Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Endocrine Disruptor Testing revenue, projected growth trends, production technology, application and end-user industry.

Endocrine Disruptor Testing Segment by Company

Charles River Laboratories

Labcorp

Eurofins Scientific

PerkinElmer

Intertek

Smithers

LAUS

Xenometrix

ToxStrategies

Fera Science

Compliance Services International

Staphyt

Creative Proteomics

Creative Bioarray

Endocrine Disruptor Testing Segment by Type

In Vitro (Cell-based) Testing

In Vivo (Animal) Testing

In Silico (Computational) Modeling

Others

Endocrine Disruptor Testing Segment by Application

Environmental Monitoring

Food Safety

Cosmetics and Personal Care Products

Public Health and Disease Prevention

Others

Endocrine Disruptor Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endocrine Disruptor Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Endocrine Disruptor Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endocrine Disruptor Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Endocrine Disruptor Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Endocrine Disruptor Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Endocrine Disruptor Testing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Endocrine Disruptor Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. In Vitro (Cell-based) Testing Major Player Table 3. In Vivo (Animal) Testing Major Player Table 4. In Silico (Computational) Modeling Major Player Table 5. Others Major Player Table 6. Global Endocrine Disruptor Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Environmental Monitoring Major Player Table 8. Food Safety Major Player Table 9. Cosmetics and Personal Care Products Major Player Table 10. Public Health and Disease Prevention Major Player Table 11. Others Major Player Table 12. Endocrine Disruptor Testing Industry Trends Table 13. Endocrine Disruptor Testing Industry Drivers Table 14. Endocrine Disruptor Testing Industry Opportunities and Challenges Table 15. Endocrine Disruptor Testing Industry Restraints Table 16. Global Endocrine Disruptor Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Endocrine Disruptor Testing Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Endocrine Disruptor Testing Market Share by Region (2021-2026) Table 19. Global Endocrine Disruptor Testing Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Endocrine Disruptor Testing Market Share by Region (2027-2032) Table 21. Global Endocrine Disruptor Testing Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Endocrine Disruptor Testing Revenue Market Share by Players (2021-2026) Table 23. Global Endocrine Disruptor Testing Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Endocrine Disruptor Testing Key Players Headquarters & Area Served Table 25. Global Endocrine Disruptor Testing Players, Product Type & Application Table 26. Global Endocrine Disruptor Testing Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Endocrine Disruptor Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Endocrine Disruptor Testing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Endocrine Disruptor Testing Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Endocrine Disruptor Testing Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Endocrine Disruptor Testing Revenue Market Share by Type (2021-2026) Table 33. Global Endocrine Disruptor Testing Revenue Market Share by Type (2027-2032) Table 34. Global Endocrine Disruptor Testing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Endocrine Disruptor Testing Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Endocrine Disruptor Testing Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Endocrine Disruptor Testing Revenue Market Share by Application (2021-2026) Table 38. Global Endocrine Disruptor Testing Revenue Market Share by Application (2027-2032) Table 39. Charles River Laboratories Company Information Table 40. Charles River Laboratories Business Overview Table 41. Charles River Laboratories Endocrine Disruptor Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Charles River Laboratories Endocrine Disruptor Testing Product Portfolio Table 43. Charles River Laboratories Recent Development Table 44. Labcorp Company Information Table 45. Labcorp Business Overview Table 46. Labcorp Endocrine Disruptor Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Labcorp Endocrine Disruptor Testing Product Portfolio Table 48. Labcorp Recent Development Table 49. Eurofins Scientific Company Information Table 50. Eurofins Scientific Business Overview Table 51. Eurofins Scientific Endocrine Disruptor Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Eurofins Scientific Endocrine Disruptor Testing Product Portfolio Table 53. Eurofins Scientific Recent Development Table 54. PerkinElmer Company Information Table 55. PerkinElmer Business Overview Table 56. PerkinElmer Endocrine Disruptor Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. PerkinElmer Endocrine Disruptor Testing Product Portfolio Table 58. PerkinElmer Recent Development Table 59. Intertek Company Information Table 60. Intertek Business Overview Table 61. Intertek Endocrine Disruptor Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Intertek Endocrine Disruptor Testing Product Portfolio Table 63. Intertek Recent Development Table 64. Smithers Company Information Table 65. Smithers Business Overview Table 66. Smithers Endocrine Disruptor Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Smithers Endocrine Disruptor Testing Product Portfolio Table 68. Smithers Recent Development Table 69. LAUS Company Information Table 70. LAUS Business Overview Table 71. LAUS Endocrine Disruptor Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. LAUS Endocrine Disruptor Testing Product Portfolio Table 73. LAUS Recent Development Table 74. Xenometrix Company Information Table 75. Xenometrix Business Overview Table 76. Xenometrix Endocrine Disruptor Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Xenometrix Endocrine Disruptor Testing Product Portfolio Table 78. Xenometrix Recent Development Table 79. ToxStrategies Company Information Table 80. ToxStrategies Business Overview Table 81. ToxStrategies Endocrine Disruptor Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. ToxStrategies Endocrine Disruptor Testing Product Portfolio Table 83. ToxStrategies Recent Development Table 84. Fera Science Company Information Table 85. Fera Science Business Overview Table 86. Fera Science Endocrine Disruptor Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Fera Science Endocrine Disruptor Testing Product Portfolio Table 88. Fera Science Recent Development Table 89. Compliance Services International Company Information Table 90. Compliance Services International Business Overview Table 91. Compliance Services International Endocrine Disruptor Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Compliance Services International Endocrine Disruptor Testing Product Portfolio Table 93. Compliance Services International Recent Development Table 94. Staphyt Company Information Table 95. Staphyt Business Overview Table 96. Staphyt Endocrine Disruptor Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Staphyt Endocrine Disruptor Testing Product Portfolio Table 98. Staphyt Recent Development Table 99. Creative Proteomics Company Information Table 100. Creative Proteomics Business Overview Table 101. Creative Proteomics Endocrine Disruptor Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Creative Proteomics Endocrine Disruptor Testing Product Portfolio Table 103. Creative Proteomics Recent Development Table 104. Creative Bioarray Company Information Table 105. Creative Bioarray Business Overview Table 106. Creative Bioarray Endocrine Disruptor Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Creative Bioarray Endocrine Disruptor Testing Product Portfolio Table 108. Creative Bioarray Recent Development Table 109. North America Endocrine Disruptor Testing Revenue by Type (2021-2026) & (US$ Million) Table 110. North America Endocrine Disruptor Testing Revenue by Type (2027-2032) & (US$ Million) Table 111. North America Endocrine Disruptor Testing Revenue by Application (2021-2026) & (US$ Million) Table 112. North America Endocrine Disruptor Testing Revenue by Application (2027-2032) & (US$ Million) Table 113. North America Endocrine Disruptor Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. North America Endocrine Disruptor Testing Revenue by Country (2021-2026) & (US$ Million) Table 115. North America Endocrine Disruptor Testing Revenue by Country (US$ Million) & (2027-2032) Table 116. Europe Endocrine Disruptor Testing Revenue by Type (2021-2026) & (US$ Million) Table 117. Europe Endocrine Disruptor Testing Revenue by Type (2027-2032) & (US$ Million) Table 118. Europe Endocrine Disruptor Testing Revenue by Application (2021-2026) & (US$ Million) Table 119. Europe Endocrine Disruptor Testing Revenue by Application (2027-2032) & (US$ Million) Table 120. Europe Endocrine Disruptor Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. Europe Endocrine Disruptor Testing Revenue by Country (2021-2026) & (US$ Million) Table 122. Europe Endocrine Disruptor Testing Revenue by Country (US$ Million) & (2027-2032) Table 123. China Endocrine Disruptor Testing Revenue by Type (2021-2026) & (US$ Million) Table 124. China Endocrine Disruptor Testing Revenue by Type (2027-2032) & (US$ Million) Table 125. China Endocrine Disruptor Testing Revenue by Application (2021-2026) & (US$ Million) Table 126. China Endocrine Disruptor Testing Revenue by Application (2027-2032) & (US$ Million) Table 127. Asia Endocrine Disruptor Testing Revenue by Type (2021-2026) & (US$ Million) Table 128. Asia Endocrine Disruptor Testing Revenue by Type (2027-2032) & (US$ Million) Table 129. Asia Endocrine Disruptor Testing Revenue by Application (2021-2026) & (US$ Million) Table 130. Asia Endocrine Disruptor Testing Revenue by Application (2027-2032) & (US$ Million) Table 131. Asia Endocrine Disruptor Testing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 132. Asia Endocrine Disruptor Testing Revenue by Region (US$ Million) & (2021-2026) Table 133. Asia Endocrine Disruptor Testing Revenue by Region (US$ Million) & (2027-2032) Table 134. SAMEA Endocrine Disruptor Testing Revenue by Type (2021-2026) & (US$ Million) Table 135. SAMEA Endocrine Disruptor Testing Revenue by Type (2027-2032) & (US$ Million) Table 136. SAMEA Endocrine Disruptor Testing Revenue by Application (2021-2026) & (US$ Million) Table 137. SAMEA Endocrine Disruptor Testing Revenue by Application (2027-2032) & (US$ Million) Table 138. SAMEA Endocrine Disruptor Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. SAMEA Endocrine Disruptor Testing Revenue by Country (2021-2026) & (US$ Million) Table 140. SAMEA Endocrine Disruptor Testing Revenue by Country (US$ Million) & (2027-2032) Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Endocrine Disruptor Testing Image Figure 2. Global Endocrine Disruptor Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Endocrine Disruptor Testing Market Size Share 2021 VS 2025 VS 2032 Figure 4. In Vitro (Cell-based) Testing Image Figure 5. In Vivo (Animal) Testing Image Figure 6. In Silico (Computational) Modeling Image Figure 7. Others Image Figure 8. Global Endocrine Disruptor Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Endocrine Disruptor Testing Market Size Share 2021 VS 2025 VS 2032 Figure 10. Environmental Monitoring Image Figure 11. Food Safety Image Figure 12. Cosmetics and Personal Care Products Image Figure 13. Public Health and Disease Prevention Image Figure 14. Others Image Figure 15. Global Endocrine Disruptor Testing Market Size (US$ Million) & (2021-2032) Figure 16. Global Endocrine Disruptor Testing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Endocrine Disruptor Testing Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Endocrine Disruptor Testing Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Endocrine Disruptor Testing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Endocrine Disruptor Testing Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Endocrine Disruptor Testing Revenue Market Share by Type (2021-2032) Figure 23. Global Endocrine Disruptor Testing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Endocrine Disruptor Testing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Endocrine Disruptor Testing Revenue Market Share by Application (2021-2032) Figure 26. North America Endocrine Disruptor Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Endocrine Disruptor Testing Revenue Share by Type (2021-2032) Figure 28. North America Endocrine Disruptor Testing Revenue Share by Application (2021-2032) Figure 29. North America Endocrine Disruptor Testing Revenue Share by Country (2021-2032) Figure 30. United States Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Endocrine Disruptor Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Endocrine Disruptor Testing Revenue Share by Type (2021-2032) Figure 35. Europe Endocrine Disruptor Testing Revenue Share by Application (2021-2032) Figure 36. Europe Endocrine Disruptor Testing Revenue Share by Country (2021-2032) Figure 37. Germany Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Endocrine Disruptor Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Endocrine Disruptor Testing Revenue Share by Type (2021-2032) Figure 47. China Endocrine Disruptor Testing Revenue Share by Application (2021-2032) Figure 48. Asia Endocrine Disruptor Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Endocrine Disruptor Testing Revenue Share by Type (2021-2032) Figure 50. Asia Endocrine Disruptor Testing Revenue Share by Application (2021-2032) Figure 51. Asia Endocrine Disruptor Testing Revenue Share by Region (2021-2032) Figure 52. Japan Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Endocrine Disruptor Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Endocrine Disruptor Testing Revenue Share by Type (2021-2032) Figure 60. SAMEA Endocrine Disruptor Testing Revenue Share by Application (2021-2032) Figure 61. SAMEA Endocrine Disruptor Testing Revenue Share by Country (2021-2032) Figure 62. Brazil Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Endocrine Disruptor Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • In Vitro (Cell-based) Testing
  • In Vivo (Animal) Testing
  • In Silico (Computational) Modeling
  • Others
Applications
  • Environmental Monitoring
  • Food Safety
  • Cosmetics and Personal Care Products
  • Public Health and Disease Prevention
  • Others
Companies covered
  • Charles River Laboratories
  • Labcorp
  • Eurofins Scientific
  • PerkinElmer
  • Intertek
  • Smithers
  • LAUS
  • Xenometrix
  • ToxStrategies
  • Fera Science
  • Compliance Services International
  • Staphyt
  • Creative Proteomics
  • Creative Bioarray

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Endocrine Disruptor Testing Market by Type
  3. 1.2.1 Global Endocrine Disruptor Testing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 In Vitro (Cell-based) Testing
  5. 1.2.3 In Vivo (Animal) Testing
  6. 1.2.4 In Silico (Computational) Modeling
  7. 1.2.5 Others
  8. 1.3 Endocrine Disruptor Testing Market by Application
  9. 1.3.1 Global Endocrine Disruptor Testing Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Environmental Monitoring
  11. 1.3.3 Food Safety
  12. 1.3.4 Cosmetics and Personal Care Products
  13. 1.3.5 Public Health and Disease Prevention
  14. 1.3.6 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Endocrine Disruptor Testing Market Dynamics
  1. 2.1 Endocrine Disruptor Testing Industry Trends
  2. 2.2 Endocrine Disruptor Testing Industry Drivers
  3. 2.3 Endocrine Disruptor Testing Industry Opportunities and Challenges
  4. 2.4 Endocrine Disruptor Testing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Endocrine Disruptor Testing Market Perspective (2021-2032)
  2. 3.2 Global Endocrine Disruptor Testing Growth Trends by Region
  3. 3.2.1 Global Endocrine Disruptor Testing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Endocrine Disruptor Testing Market Size by Region (2021-2026)
  5. 3.2.3 Global Endocrine Disruptor Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Endocrine Disruptor Testing Revenue by Players
  2. 4.1.1 Global Endocrine Disruptor Testing Revenue by Players (2021-2026)
  3. 4.1.2 Global Endocrine Disruptor Testing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Endocrine Disruptor Testing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Endocrine Disruptor Testing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Endocrine Disruptor Testing Key Players Headquarters & Area Served
  7. 4.4 Global Endocrine Disruptor Testing Players, Product Type & Application
  8. 4.5 Global Endocrine Disruptor Testing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Endocrine Disruptor Testing Market CR5 and HHI
  11. 4.6.3 2025 Endocrine Disruptor Testing Tier 1, Tier 2, and Tier 3
5 Endocrine Disruptor Testing Market Size by Type
  1. 5.1 Global Endocrine Disruptor Testing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Endocrine Disruptor Testing Revenue by Type (2021-2032)
  3. 5.3 Global Endocrine Disruptor Testing Revenue Market Share by Type (2021-2032)
6 Endocrine Disruptor Testing Market Size by Application
  1. 6.1 Global Endocrine Disruptor Testing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Endocrine Disruptor Testing Revenue by Application (2021-2032)
  3. 6.3 Global Endocrine Disruptor Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Charles River Laboratories
  2. 7.1.1 Charles River Laboratories Company Information
  3. 7.1.2 Charles River Laboratories Business Overview
  4. 7.1.3 Charles River Laboratories Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Charles River Laboratories Endocrine Disruptor Testing Product Portfolio
  6. 7.1.5 Charles River Laboratories Recent Developments
  7. 7.2 Labcorp
  8. 7.2.1 Labcorp Company Information
  9. 7.2.2 Labcorp Business Overview
  10. 7.2.3 Labcorp Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Labcorp Endocrine Disruptor Testing Product Portfolio
  12. 7.2.5 Labcorp Recent Developments
  13. 7.3 Eurofins Scientific
  14. 7.3.1 Eurofins Scientific Company Information
  15. 7.3.2 Eurofins Scientific Business Overview
  16. 7.3.3 Eurofins Scientific Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eurofins Scientific Endocrine Disruptor Testing Product Portfolio
  18. 7.3.5 Eurofins Scientific Recent Developments
  19. 7.4 PerkinElmer
  20. 7.4.1 PerkinElmer Company Information
  21. 7.4.2 PerkinElmer Business Overview
  22. 7.4.3 PerkinElmer Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 PerkinElmer Endocrine Disruptor Testing Product Portfolio
  24. 7.4.5 PerkinElmer Recent Developments
  25. 7.5 Intertek
  26. 7.5.1 Intertek Company Information
  27. 7.5.2 Intertek Business Overview
  28. 7.5.3 Intertek Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Intertek Endocrine Disruptor Testing Product Portfolio
  30. 7.5.5 Intertek Recent Developments
  31. 7.6 Smithers
  32. 7.6.1 Smithers Company Information
  33. 7.6.2 Smithers Business Overview
  34. 7.6.3 Smithers Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Smithers Endocrine Disruptor Testing Product Portfolio
  36. 7.6.5 Smithers Recent Developments
  37. 7.7 LAUS
  38. 7.7.1 LAUS Company Information
  39. 7.7.2 LAUS Business Overview
  40. 7.7.3 LAUS Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  41. 7.7.4 LAUS Endocrine Disruptor Testing Product Portfolio
  42. 7.7.5 LAUS Recent Developments
  43. 7.8 Xenometrix
  44. 7.8.1 Xenometrix Company Information
  45. 7.8.2 Xenometrix Business Overview
  46. 7.8.3 Xenometrix Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Xenometrix Endocrine Disruptor Testing Product Portfolio
  48. 7.8.5 Xenometrix Recent Developments
  49. 7.9 ToxStrategies
  50. 7.9.1 ToxStrategies Company Information
  51. 7.9.2 ToxStrategies Business Overview
  52. 7.9.3 ToxStrategies Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  53. 7.9.4 ToxStrategies Endocrine Disruptor Testing Product Portfolio
  54. 7.9.5 ToxStrategies Recent Developments
  55. 7.10 Fera Science
  56. 7.10.1 Fera Science Company Information
  57. 7.10.2 Fera Science Business Overview
  58. 7.10.3 Fera Science Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Fera Science Endocrine Disruptor Testing Product Portfolio
  60. 7.10.5 Fera Science Recent Developments
  61. 7.11 Compliance Services International
  62. 7.11.1 Compliance Services International Company Information
  63. 7.11.2 Compliance Services International Business Overview
  64. 7.11.3 Compliance Services International Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Compliance Services International Endocrine Disruptor Testing Product Portfolio
  66. 7.11.5 Compliance Services International Recent Developments
  67. 7.12 Staphyt
  68. 7.12.1 Staphyt Company Information
  69. 7.12.2 Staphyt Business Overview
  70. 7.12.3 Staphyt Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Staphyt Endocrine Disruptor Testing Product Portfolio
  72. 7.12.5 Staphyt Recent Developments
  73. 7.13 Creative Proteomics
  74. 7.13.1 Creative Proteomics Company Information
  75. 7.13.2 Creative Proteomics Business Overview
  76. 7.13.3 Creative Proteomics Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Creative Proteomics Endocrine Disruptor Testing Product Portfolio
  78. 7.13.5 Creative Proteomics Recent Developments
  79. 7.14 Creative Bioarray
  80. 7.14.1 Creative Bioarray Company Information
  81. 7.14.2 Creative Bioarray Business Overview
  82. 7.14.3 Creative Bioarray Endocrine Disruptor Testing Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Creative Bioarray Endocrine Disruptor Testing Product Portfolio
  84. 7.14.5 Creative Bioarray Recent Developments
8 North America
  1. 8.1 North America Endocrine Disruptor Testing Revenue (2021-2032)
  2. 8.2 North America Endocrine Disruptor Testing Revenue by Type (2021-2032)
  3. 8.2.1 North America Endocrine Disruptor Testing Revenue by Type (2021-2026)
  4. 8.2.2 North America Endocrine Disruptor Testing Revenue by Type (2027-2032)
  5. 8.3 North America Endocrine Disruptor Testing Revenue Share by Type (2021-2032)
  6. 8.4 North America Endocrine Disruptor Testing Revenue by Application (2021-2032)
  7. 8.4.1 North America Endocrine Disruptor Testing Revenue by Application (2021-2026)
  8. 8.4.2 North America Endocrine Disruptor Testing Revenue by Application (2027-2032)
  9. 8.5 North America Endocrine Disruptor Testing Revenue Share by Application (2021-2032)
  10. 8.6 North America Endocrine Disruptor Testing Revenue by Country
  11. 8.6.1 North America Endocrine Disruptor Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Endocrine Disruptor Testing Revenue by Country (2021-2026)
  13. 8.6.3 North America Endocrine Disruptor Testing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Endocrine Disruptor Testing Revenue (2021-2032)
  2. 9.2 Europe Endocrine Disruptor Testing Revenue by Type (2021-2032)
  3. 9.2.1 Europe Endocrine Disruptor Testing Revenue by Type (2021-2026)
  4. 9.2.2 Europe Endocrine Disruptor Testing Revenue by Type (2027-2032)
  5. 9.3 Europe Endocrine Disruptor Testing Revenue Share by Type (2021-2032)
  6. 9.4 Europe Endocrine Disruptor Testing Revenue by Application (2021-2032)
  7. 9.4.1 Europe Endocrine Disruptor Testing Revenue by Application (2021-2026)
  8. 9.4.2 Europe Endocrine Disruptor Testing Revenue by Application (2027-2032)
  9. 9.5 Europe Endocrine Disruptor Testing Revenue Share by Application (2021-2032)
  10. 9.6 Europe Endocrine Disruptor Testing Revenue by Country
  11. 9.6.1 Europe Endocrine Disruptor Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Endocrine Disruptor Testing Revenue by Country (2021-2026)
  13. 9.6.3 Europe Endocrine Disruptor Testing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Endocrine Disruptor Testing Revenue (2021-2032)
  2. 10.2 China Endocrine Disruptor Testing Revenue by Type (2021-2032)
  3. 10.2.1 China Endocrine Disruptor Testing Revenue by Type (2021-2026)
  4. 10.2.2 China Endocrine Disruptor Testing Revenue by Type (2027-2032)
  5. 10.3 China Endocrine Disruptor Testing Revenue Share by Type (2021-2032)
  6. 10.4 China Endocrine Disruptor Testing Revenue by Application (2021-2032)
  7. 10.4.1 China Endocrine Disruptor Testing Revenue by Application (2021-2026)
  8. 10.4.2 China Endocrine Disruptor Testing Revenue by Application (2027-2032)
  9. 10.5 China Endocrine Disruptor Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Endocrine Disruptor Testing Revenue (2021-2032)
  2. 11.2 Asia Endocrine Disruptor Testing Revenue by Type (2021-2032)
  3. 11.2.1 Asia Endocrine Disruptor Testing Revenue by Type (2021-2026)
  4. 11.2.2 Asia Endocrine Disruptor Testing Revenue by Type (2027-2032)
  5. 11.3 Asia Endocrine Disruptor Testing Revenue Share by Type (2021-2032)
  6. 11.4 Asia Endocrine Disruptor Testing Revenue by Application (2021-2032)
  7. 11.4.1 Asia Endocrine Disruptor Testing Revenue by Application (2021-2026)
  8. 11.4.2 Asia Endocrine Disruptor Testing Revenue by Application (2027-2032)
  9. 11.5 Asia Endocrine Disruptor Testing Revenue Share by Application (2021-2032)
  10. 11.6 Asia Endocrine Disruptor Testing Revenue by Country
  11. 11.6.1 Asia Endocrine Disruptor Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Endocrine Disruptor Testing Revenue by Country (2021-2026)
  13. 11.6.3 Asia Endocrine Disruptor Testing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Endocrine Disruptor Testing Revenue (2021-2032)
  2. 12.2 SAMEA Endocrine Disruptor Testing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Endocrine Disruptor Testing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Endocrine Disruptor Testing Revenue by Type (2027-2032)
  5. 12.3 SAMEA Endocrine Disruptor Testing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Endocrine Disruptor Testing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Endocrine Disruptor Testing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Endocrine Disruptor Testing Revenue by Application (2027-2032)
  9. 12.5 SAMEA Endocrine Disruptor Testing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Endocrine Disruptor Testing Revenue by Country
  11. 12.6.1 SAMEA Endocrine Disruptor Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Endocrine Disruptor Testing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Endocrine Disruptor Testing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst